Alterity Therapeutics (ATHE) announced the appointment of Ann Cunningham to its Board of Directors as an independent Non-Executive Director, effective 17th April 2026. Cunningham’s appointment further strengthens Alterity’s Board composition, adding significant global commercial and strategic expertise as the Company transitions toward late-stage development in Multiple System Atrophy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE: